An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling component of the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Leong, Steven R., Sukumaran, Siddharth, Hristopoulos, Maria, Totpal, Klara, Stainton, Shannon, Lu, Elizabeth, Wong, Alfred, Tam, Lucinda, Newman, Robert, Vuillemenot, Brian R., Ellerman, Diego, Gu, Chen, Mathieu, Mary, Dennis, Mark S., Nguyen, Allen, Zheng, Bing, Zhang, Crystal, Lee, Genee, Chu, Yu-Waye, Prell, Rodney A., Lin, Kedan, Laing, Steven T., Polson, Andrew G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2017
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290988/
https://ncbi.nlm.nih.gov/pubmed/27908880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-08-735365
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi